A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
Completed · Phase 1 · NCT07137689
Conditions: Renal Insufficiency
At a glance
- Research payments reported, 2025
- $385,703
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3537982 (drug)
- Dates
- Started 2025-08-18; completion 2026-04-10
- Results posted
- Not yet
The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.
From ClinicalTrials.gov, last updated 2026-04-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $385,703 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Victoria C. Helow, M.D. Specialist · Jacksonville, FL
- Thomas C. Marbury, M.D. Nephrology (Kidney) · Orlando, FL
- Jesus Navarro, M.D. Nephrology (Kidney) · Tampa, FL
- Robert G. Perry, M.D Internal Medicine · Pembroke Pines, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Genesis Clinical Research $213,216
- Orlando Clinical Research Center Inc $107,244
- Panax Clinical Research LLC $64,952
- Jacksonville Center for Clinical Research $290
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.